Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.
Completed
- Conditions
- DiabetesDiabetes Mellitus
- Interventions
- Biological: Blood draw
- Registration Number
- NCT01809093
- Lead Sponsor
- MidAtlantic Retina
- Brief Summary
You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.
- Detailed Description
The hypothesis tested here is that diabetic patients that express the higher molecular weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level and, as a result, are at a greater risk for the development of more severe diabetic retinopathy.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Diabetes Mellitus
- Undergoing pars plana vitrectomy for any reason
Exclusion Criteria
- Use of any anti-VEGF (vascular endothelial growth factor ) medications
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Blood draw Blood draw Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
- Primary Outcome Measures
Name Time Method Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma up to 6 months Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mid Atlantic Retina- Wills Eye Institute
🇺🇸Philadelphia, Pennsylvania, United States